No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SNPX Synaptogenix
- 4.2800
- -0.2100-4.68%
Close Jul 22 16:00 ET
- 4.4900
- +0.2100+4.91%
Post 16:32 ET
5.28MMarket Cap-183P/E (TTM)
4.3900High4.2001Low14.56KVolume4.3115Open4.4900Pre Close62.07KTurnover1.21%Turnover RatioLossP/E (Static)1.23MShares19.725052wk High0.24P/B5.16MFloat Cap3.527552wk Low--Dividend TTM1.21MShs Float362.5000Historical High--Div YieldTTM4.23%Amplitude3.5250Historical Low4.2610Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Synaptogenix Announces New Collaboration With Lsu Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/11/2024 202.38% Maxim Group → $14 Upgrades Hold → Buy 12/19/2022 — Maxim Group Downgrades Buy → Hold 0
Maxim Group Upgrades Synaptogenix(SNPX.US) to Buy Rating, Announces Target Price $14
Maxim Group analyst Jason McCarthy upgrades $Synaptogenix(SNPX.US)$ to a buy rating, and sets the target price at $14.According to TipRanks data, the analyst has a success rate of 24.0% and a total
Express News | Synaptogenix Inc : Maxim Group Raises to Buy From Hold
Express News | Synaptogenix Announces FDA Authorization Of Its Investigational New Drug Application For Bryostatin-1 Trial In Multiple Sclerosis
Express News | Synaptogenix Announces FDA Authorization of Ind Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis
Comments
$Synaptogenix(SNPX.US$
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix (NASDAQ: SNPX) has announced a new collaboration with LSU Health New Orleans' Neuroscience Center of Excellence to test its polyunsaturated fatty acid (PUFA) analogs for treating spinal cord injury (SCI). The company also received US Patent No. 12,016,837 for its PUFA analogs in treating neurodegenerative diseases.
The study will com...
Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury
Synaptogenix (NASDAQ: SNPX) has announced a new collaboration with LSU Health New Orleans' Neuroscience Center of Excellence to test its polyunsaturated fatty acid (PUFA) analogs for treating spinal cord injury (SCI). The company also received US Patent No. 12,016,837 for its PUFA analogs in treating neurodegenerative diseases.
The study will com...
$Synaptogenix(SNPX.US$ Reuters· just
Synaptogenix Announces FDA Authorization of Ind Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis
Synaptogenix Announces FDA Authorization of Ind Application for Clinical Trial for Bryostatin-1 in Multiple Sclerosis
my man
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg